Cardiology
Conference Coverage
New trial suggests CV benefit with EPA: RESPECT-EPA
The open-label trial could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose...
Conference Coverage
Precision CAD testing shows 70% cut in composite risk at 1 year
A streamlined protocol for evaluating suspected stable chest pain substantially improved outcomes at 1 year in the PRECISE trial.
Conference Coverage
Avoid routine early ECMO in severe cardiogenic shock: ECMO-CS
Early ECMO in this setting is increasingly common, but it didn’t seem to improve outcomes in the trial, compared with a more conservative approach...
Conference Coverage
No survival advantage for either torsemide or furosemide in HF: TRANSFORM-HF
One loop diuretic is the most widely used in heart failure, the other may have advantages in some situations, but there’s been no head-to-head...
Conference Coverage
Acute heart failure risk assessment in ED improves outcomes: COACH
Systematic risk assessment of patients with acute heart failure in the ED significantly cut their 30-day and 20-month cardiovascular...
Conference Coverage
Puzzling, unique ECG from pig-to-human transplanted heart
The postimplantation electrocardiogram from the first pig heart xenotransplantation resembled neither a pig nor a human ECG, with unknown...
Conference Coverage
Diuretic agents equal to prevent CV events in hypertension: DCP
Cardiovascular events were nearly identical with two different hypertension drugs in the randomized Diuretic Comparison Project trial.
Conference Coverage
Triglyceride-lowering fails to show CV benefit in large fibrate trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on...
Conference Coverage
Uptake of high-sensitivity troponin assays lags in U.S. hospitals
A national analysis found that only one-third of hospitals are utilizing the assays, despite the first test being approved in 2017.
News
Best anticoagulant for minimizing bleeding risk identified
“Apixaban stood out as having lower risk of gastrointestinal bleeding.”